DOCSLIB.ORG

Vaccinia Virus Protein A40 Is an Immunomodulator

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Vaccinia Virus Protein A40 Is an Immunomodulator Vaccinia virus protein A40 is an immunomodulator Susan Anne Jarmin IMPERIAL COLLEGE LONDON Department of Virology A thesis submitted for the degree of PhD 2009 1 Declaration The work detailed herein is the work of the candidate except where clearly indicated. The in vivo animal injections were undertaken by Dr. Ron A-J Chen. The leukocyte infiltration flow cytometry analysis and cytotoxicity assay on extracted cells detailed herein were undertaken in a collaborative manner with Dr. Nathalie Jacobs. The polyclonal anti-A40 antibody was generated by Harlan Sera-Lab (Leicestershire, England). ------------------------------------------------------------------------ Susan A. Jarmin 2 Acknowledgements Sincere thanks go to Professor Geoffrey L. Smith for his support, guidance and encouragement. It has been a pleasure and a privilege to undertake the work detailed in this thesis. I am immensely grateful to have been given the opportunity to work in his lab, in an environment that was so inspiring and supportive. I was fortunate to have the guidance and expertise of my co-supervisor Dr. Nathalie Jacobs for the first half of my studies. I am grateful for her mentoring and the supply of Belgian chocolate. To Dr Ron Chen, a big thank you for all the help and encouragement and probably wasted Chinese lessons. To all members of the GLS lab, past and present, thank you for making the experience enjoyable and rewarding. To my fellow PhD students, Adi and Rory, thank you for your support, friendship, laughs and help over the last three years; Laura for her friendship and support in keeping me relatively sane this last year; Kim, those support and unwavering supply of an ear to listen to me and a gentle reminder to relax have often kept me sane. Claire and Mike, your camaraderie and dancing were greatly appreciated. A big thank you is also due to Dr Mike Skinner and Dr Stephen Laidlaw for all their support and guidance over the years. Finally, thanks to my family, for their support, encouragement and a source of inspiration and unquestioning love. To my parents, a huge thank you for their support, guidance and unwavering patience. To my sister, Sarah, thank you for all your help and support and for being bribed with JellyTots. To my brother, for being a patient listener and pillar of support. All your love and support has been greatly appreciated and I thank you for the gentle nudging along the way. 3 Abstract Vaccinia virus (VACV) strain Western Reserve gene A40R encodes a type II membrane glycoprotein with a C-type lectin-like domain at the C terminus. The A40 protein is not incorporated into virions, is nonessential for virus replication in cell culture and does not affect virus virulence in a murine intranasal model of infection. However, A40 does affect the outcome of infection in an intradermal infection model in which the virus lacking gene A40R produced smaller lesions and alterations in the host immune response. A40 has amino acid similarity to C-type lectins, such as NKG2A and DC- SIGN. This observation together with its location on the infected cell surface and its ability to bind to the surface of cells of the immune system is consistent with A40 functioning as an immunomodulator. It is possible that A40 might function by mimicking native host lectins or by modulating recognition of VACV-infected cells by cells of the immune system. To investigate the mechanism by which A40 affects the outcome of infection in vivo, a cloning and experimental strategy was devised to search for its ligand(s) and try to determine its structure in collaboration with protein crystallographers. To achieve these goals, the recombinant A40 protein has been produced in E. coli, mammalian cells, and from insect cells infected with recombinant baculoviruses. Bacterially expressed recombinant A40 was used to generate an antibody specific to A40 and this was then purified, characterised and used to further the characterisation of A40. The potential for A40 to interact with a ligand on the surface of another cell was investigated by a cell binding assay using recombinant A40 protein. This protein was produced in a mammalian system and was found to bind to the surface of immune cells but not to epithelial cells. In cytotoxicity assays, the absence or over-expression of A40 was found to modulate the ability of NK cells to kill VACV infected cells. 4 Contents Declaration ................................................................................................................................................. 2 Acknowledgements .................................................................................................................................... 3 Abstract ...................................................................................................................................................... 4 Contents ..................................................................................................................................................... 5 Table of figures ........................................................................................................................................ 12 Table of tables .......................................................................................................................................... 13 Abbreviations .......................................................................................................................................... 14 Chapter 1. Introduction ..................................................................................................................... 29 1.1 Introduction to poxviruses and their historical significance....................................................... 29 1.2 Genome structure of OPVs ......................................................................................................... 31 1.3 Virion structure ........................................................................................................................... 32 1.4 VACV life cycle ........................................................................................................................... 33 1.4.1 Virus binding ..................................................................................................................... 33 1.4.2 Virus entry ......................................................................................................................... 33 1.4.3 Gene Expression ................................................................................................................ 34 1.4.4 DNA replication ................................................................................................................ 37 1.4.5 Virus assembly, maturation & release ............................................................................... 37 1.5 Effect of VACV on host cells ....................................................................................................... 38 1.6 Use of VACV in medical research ............................................................................................... 41 1.6.1 VACV-based vaccines ...................................................................................................... 41 1.6.2 VACV-based oncotherapy................................................................................................. 42 1.7 Innate immune response to VACV infection ................................................................................ 43 1.7.1 Complement ...................................................................................................................... 44 1.8 Innate immune cells .................................................................................................................... 45 1.8.1 Neutrophils ........................................................................................................................ 45 1.8.2 Macrophages ..................................................................................................................... 46 5 1.8.3 Natural killer cells ............................................................................................................. 47 1.8.4 NKT cells .......................................................................................................................... 54 1.8.5 Importance of C-type lectins in immune response ............................................................ 54 1.8.6 DCs .................................................................................................................................... 60 1.8.7 T cell receptor γδ cells ....................................................................................................... 61 1.9 Pattern recognition receptors (PRRs) ......................................................................................... 61 1.9.1 Toll-like receptors (TLRs) ................................................................................................. 62 1.9.2 Soluble PRRs ..................................................................................................................... 66 1.9.3 Soluble mediators of immune response ............................................................................. 68 1.10 Apoptosis ................................................................................................................................ 74 1.11 Adaptive immune responses to VACV infection ....................................................................
Load more

Recommended publications
  • Adams Hawii 0085O 10232.Pdf
    ANALYSIS AND DEVELOPMENT OF MANAGEMENT TOOLS FOR ORYCTES RHINOCEROS (COLEOPTERA: SCARABAEIDAE) A THESIS SUBMITTED TO THE GRAUDATE DIVISION OF THE UNIVERSITY OF HAWAIʻI AT MĀNOA IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF MASTER OF SCIENCE IN TROPICAL PLANT PATHOLOGY MAY 2019 By Brandi-Leigh H. Adams Thesis Committee: Michael Melzer, Chairperson Zhiqiang Cheng Brent Sipes ACKNOWLEDGEMENTS It is with deep gratitude that I thank the members of my committee, Dr. Michael Melzer, Dr. Zhiqiang Cheng, and Dr. Brent Sipes for their expert advice and knowledge, to which I have constantly deferred to during my time as a graduate student. A very special thank you goes to Dr. Michael Melzer, who took me in as an undergraduate lab assistant, and saw enough potential in me that he felt I deserved the opportunity to learn, travel, and grow under his guidance. I would also like to give special thanks to Dr. Shizu Watanabe, who always made time to answer even the smallest, most O.C.D. of my questions, who gave me words of encouragement when experiments did not go as planned or when I would find myself in doubt, and who has become a mentor and friend along the way. To my very first mentors in science; Dr. Wendy Kuntz, Dr. Matthew Tuthill, and Keolani Noa; thank you for encouraging me to pursue a major and career in STEM in the first place. I would also like to thank my lab mates, Nelson Masang Jr., Alexandra Kong, Alejandro Olmedo Velarde, Tomie Vowell, Asoka De Silva, Megan Manley, Jarin Loristo, and Cheyenne Barela for their support with experiments, and the knowledge and skills they have passed on to me.
    [Show full text]
  • Changes to Virus Taxonomy 2004
    Arch Virol (2005) 150: 189–198 DOI 10.1007/s00705-004-0429-1 Changes to virus taxonomy 2004 M. A. Mayo (ICTV Secretary) Scottish Crop Research Institute, Invergowrie, Dundee, U.K. Received July 30, 2004; accepted September 25, 2004 Published online November 10, 2004 c Springer-Verlag 2004 This note presents a compilation of recent changes to virus taxonomy decided by voting by the ICTV membership following recommendations from the ICTV Executive Committee. The changes are presented in the Table as decisions promoted by the Subcommittees of the EC and are grouped according to the major hosts of the viruses involved. These new taxa will be presented in more detail in the 8th ICTV Report scheduled to be published near the end of 2004 (Fauquet et al., 2004). Fauquet, C.M., Mayo, M.A., Maniloff, J., Desselberger, U., and Ball, L.A. (eds) (2004). Virus Taxonomy, VIIIth Report of the ICTV. Elsevier/Academic Press, London, pp. 1258. Recent changes to virus taxonomy Viruses of vertebrates Family Arenaviridae • Designate Cupixi virus as a species in the genus Arenavirus • Designate Bear Canyon virus as a species in the genus Arenavirus • Designate Allpahuayo virus as a species in the genus Arenavirus Family Birnaviridae • Assign Blotched snakehead virus as an unassigned species in family Birnaviridae Family Circoviridae • Create a new genus (Anellovirus) with Torque teno virus as type species Family Coronaviridae • Recognize a new species Severe acute respiratory syndrome coronavirus in the genus Coro- navirus, family Coronaviridae, order Nidovirales
    [Show full text]
  • And Γ- Cytoplasmic Actin in Vaccinia Virus Infection
    Lights, Camera, Actin: Divergent roles of β- and γ- cytoplasmic actin in vaccinia virus infection NOORUL BISHARA MARZOOK A thesis submitted in fulfillment of requirements for the degree of Doctor of Philosophy FACULTY OF SCIENCE SCHOOL OF MOLECULAR BIOSCIENCE UNIVERSITY OF SYDNEY 2017 i TABLE OF CONTENTS Table of Contents ........................................................................................................... ii Acknowledgements ....................................................................................................... v Declaration ................................................................................................................... vii Abstract ....................................................................................................................... viii List of Figures ................................................................................................................ x List of Publications Arising From This Work.............................................................. xi Abbreviations Used ..................................................................................................... xii Chapter 1: Introduction ............................................................................................... 1 1.1 The Cytoskeleton ............................................................................................................ 2 1.1.1 The Eukaryotic Cytoskeleton .....................................................................................
    [Show full text]
  • Vaccinia Virus
    APPENDIX 2 Vaccinia Virus • Accidental infection following transfer from the vac- cination site to another site (autoinoculation) or to Disease Agent: another person following intimate contact Likelihood of Secondary Transmission: • Vaccinia virus • Significant following direct contact Disease Agent Characteristics: At-Risk Populations: • Family: Poxviridae; Subfamily: Chordopoxvirinae; • Individuals receiving smallpox (vaccinia) vaccination Genus: Orthopoxvirus • Individuals who come in direct contact with vacci- • Virion morphology and size: Enveloped, biconcave nated persons core with two lateral bodies, brick-shaped to pleo- • Those at risk for more severe complications of infec- morphic virions, ~360 ¥ 270 ¥ 250 nm in size tion include the following: • Nucleic acid: Nonsegmented, linear, covalently ᭺ Immune-compromised persons including preg- closed, double-stranded DNA, 18.9-20.0 kb in length nant women • Physicochemical properties: Virus is inactivated at ᭺ Patients with atopy, especially those with eczema 60°C for 8 minutes, but antigen can withstand 100°C; ᭺ Patients with extensive exfoliative skin disease lyophilized virus maintains potency for 18 months at 4-6°C; virus may be stable when dried onto inanimate Vector and Reservoir Involved: surfaces; susceptible to 1% sodium hypochlorite, • No natural host 2% glutaraldehyde, and formaldehyde; disinfection of hands and environmental contamination with soap Blood Phase: and water are effective • Vaccinia DNA was detected by PCR in the blood in 6.5% of 77 military members from 1 to 3 weeks after Disease Name: smallpox (vaccinia) vaccination that resulted in a major skin reaction. • Progressive vaccinia (vaccinia necrosum or vaccinia • In the absence of complications after immunization, gangrenosum) recently published PCR and culture data suggest that • Generalized vaccinia viremia with current vaccines must be rare 3 weeks • Eczema vaccinatum after vaccination.
    [Show full text]
  • Diversity of Large DNA Viruses of Invertebrates ⇑ Trevor Williams A, Max Bergoin B, Monique M
    Journal of Invertebrate Pathology 147 (2017) 4–22 Contents lists available at ScienceDirect Journal of Invertebrate Pathology journal homepage: www.elsevier.com/locate/jip Diversity of large DNA viruses of invertebrates ⇑ Trevor Williams a, Max Bergoin b, Monique M. van Oers c, a Instituto de Ecología AC, Xalapa, Veracruz 91070, Mexico b Laboratoire de Pathologie Comparée, Faculté des Sciences, Université Montpellier, Place Eugène Bataillon, 34095 Montpellier, France c Laboratory of Virology, Wageningen University, Droevendaalsesteeg 1, 6708 PB Wageningen, The Netherlands article info abstract Article history: In this review we provide an overview of the diversity of large DNA viruses known to be pathogenic for Received 22 June 2016 invertebrates. We present their taxonomical classification and describe the evolutionary relationships Revised 3 August 2016 among various groups of invertebrate-infecting viruses. We also indicate the relationships of the Accepted 4 August 2016 invertebrate viruses to viruses infecting mammals or other vertebrates. The shared characteristics of Available online 31 August 2016 the viruses within the various families are described, including the structure of the virus particle, genome properties, and gene expression strategies. Finally, we explain the transmission and mode of infection of Keywords: the most important viruses in these families and indicate, which orders of invertebrates are susceptible to Entomopoxvirus these pathogens. Iridovirus Ó Ascovirus 2016 Elsevier Inc. All rights reserved. Nudivirus Hytrosavirus Filamentous viruses of hymenopterans Mollusk-infecting herpesviruses 1. Introduction in the cytoplasm. This group comprises viruses in the families Poxviridae (subfamily Entomopoxvirinae) and Iridoviridae. The Invertebrate DNA viruses span several virus families, some of viruses in the family Ascoviridae are also discussed as part of which also include members that infect vertebrates, whereas other this group as their replication starts in the nucleus, which families are restricted to invertebrates.
    [Show full text]
  • University of Florida Thesis Or Dissertation Formatting
    THE ROLE OF CELL SIGNALING IN POXVIRUS TROPISM: THE CASE OF THE M-T5 HOST-RANGE PROTEIN OF MYXOMA VIRUS By STEVEN JAMES WERDEN A DISSERTATION PRESENTED TO THE GRADUATE SCHOOL OF THE UNIVERSITY OF FLORIDA IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY UNIVERSITY OF FLORIDA 2009 1 © 2009 Steven James Werden 2 To my family 3 ACKNOWLEDGMENTS I would like to thank Dr. Grant McFadden for continuous support, encouragement and advice during the course of my PhD. I am truly grateful for all the time and energy he has spent training me to become a better scientist and critical thinker. Without his guidance and persistent help this dissertation would not have been possible. In addition, I am appreciative to my committee members, Drs. Richard Condit, Greg Schultz and Dave Bloom for their encouraging words, fruitful discussion and most importantly, their commitment to helping me succeed. During the past five years, I have had the opportunity and privilege to work with many talented individuals. I would like to acknowledge all members of the McFadden laboratory, both past and present, for creating a work environment that fostered creativity. Special thanks go to Drs.Gen Wang, Steve Nazarian, Marianne Stanford and Fuan Wang for providing technical training. Dr. John Barrett deserves a special mention for his continued mentorship and support. I must not forget to thank those who attended the weekly “Poxaholics” meetings, for providing constructive criticism and a wonderful atmosphere to present data. Thanks go out to Doug Smith for assistance with the confocal microscope and to all who contributed reagents that were used in this dissertation.
    [Show full text]
  • (ACIP) General Best Guidance for Immunization
    Appendix 1: Glossary Adverse event. An undesirable medical condition that occurs following vaccination which might be truly caused by a vaccine, or it might be pure coincidence. Adverse reaction. An undesirable medical condition that has been demonstrated to be caused by a vaccine. Evidence for the causal relation is usually obtained through randomized clinical trials, controlled epidemiologic studies, isolation of the vaccine strain from the pathogenic site, or recurrence of the condition with repeated vaccination (i.e., rechallenge); synonyms include side effect and adverse effect. Adjuvant. A vaccine component distinct from the antigen that enhances the immune response to the antigen. Antitoxin. A solution of antibodies against a toxin. Antitoxin can be derived from either human (e.g., tetanus immune globulin) or animal (usually equine) sources (e.g., diphtheria and botulism antitoxin). Antitoxins are used to confer passive immunity and for treatment. Hyperimmune globulin (specific). Special preparations obtained from blood plasma from donor pools preselected for a high antibody content against a specific antigen (e.g., hepatitis B immune globulin, varicella-zoster immune globulin, rabies immune globulin, tetanus immune globulin, vaccinia immune globulin, cytomegalovirus immune globulin, botulism immune globulin). Immune globulin. A sterile solution containing antibodies, which are usually obtained from human blood. It is obtained by cold ethanol fractionation of large pools of blood plasma and contains 15%-18% protein. Intended for intramuscular administration, immune globulin is primarily indicated for routine maintenance of immunity among certain immunodeficient persons and for passive protection against measles and hepatitis A. General Best Practice Guidelines for Immunization: Appendix 1: Glossary 189 Immunobiologic. Antigenic substances (e.g., vaccines and toxoids) or antibody- containing preparations (e.g., globulins and antitoxins) from human or animal donors.
    [Show full text]
  • ICTV Code Assigned: 2011.001Ag Officers)
    This form should be used for all taxonomic proposals. Please complete all those modules that are applicable (and then delete the unwanted sections). For guidance, see the notes written in blue and the separate document “Help with completing a taxonomic proposal” Please try to keep related proposals within a single document; you can copy the modules to create more than one genus within a new family, for example. MODULE 1: TITLE, AUTHORS, etc (to be completed by ICTV Code assigned: 2011.001aG officers) Short title: Change existing virus species names to non-Latinized binomials (e.g. 6 new species in the genus Zetavirus) Modules attached 1 2 3 4 5 (modules 1 and 9 are required) 6 7 8 9 Author(s) with e-mail address(es) of the proposer: Van Regenmortel Marc, [email protected] Burke Donald, [email protected] Calisher Charles, [email protected] Dietzgen Ralf, [email protected] Fauquet Claude, [email protected] Ghabrial Said, [email protected] Jahrling Peter, [email protected] Johnson Karl, [email protected] Holbrook Michael, [email protected] Horzinek Marian, [email protected] Keil Guenther, [email protected] Kuhn Jens, [email protected] Mahy Brian, [email protected] Martelli Giovanni, [email protected] Pringle Craig, [email protected] Rybicki Ed, [email protected] Skern Tim, [email protected] Tesh Robert, [email protected] Wahl-Jensen Victoria, [email protected] Walker Peter, [email protected] Weaver Scott, [email protected] List the ICTV study group(s) that have seen this proposal: A list of study groups and contacts is provided at http://www.ictvonline.org/subcommittees.asp .
    [Show full text]
  • The Study of Thimerosal and Autism
    The Study of Thimerosal and Autism Documentation and Codebook for the Child Vaccination Histories File: Cambridge, MA Lexington, MA Hadley, MA Bethesda, MD September 3, 2010 Chicago, IL Prepared for Frank DeStefano National Immunization Program Centers for Disease Control and Prevention Atlanta, GA 30329 Prepared by Cristofer Price Yeqin He Abt Associates Inc. Suite 800 North 4550 Montgomery Avenue Bethesda, MD 20814-3343 This documentation was prepared by Cristofer Price and Yeqin He of Abt Associates Inc. for the Immunization Safety Office (ISO) of the Centers for Disease Control and Prevention (CDC) Atlanta, GA 30333. Questions about the documentation, substantive questions, or technical issues regarding the data file should be directed to the CDC ISO, MS D26, 1600 Clifton Road, Atlanta, Georgia 30333 (404-639-8256). Suggested Citation for Study of Thimerosal and Autism Public Use Data Set: Price, C.S., He, Y. (2010) The Study of Thimerosal and Autism: Data Set Documentation. Bethesda MD: Abt Associates, Inc; Prepared for the National Immunization Program Centers for Disease Control and Prevention Atlanta, GA Abt Associates Inc. 1 Documentation and Codebook for the Child Vaccination Histories File 1. Introduction to the Child Vaccination Histories File............................................... 2 2. File Formats and Variable Descriptions................................................................... 4 1. Introduction to the Child Vaccination Histories File The Child Vaccination Histories File contains the data that were used to construct the measures of early childhood (postnatal) exposure to ethylmercury from thimerosal- containing vaccines and immune globulin preparations received by the study children during the age range spanning birth to 20 months. The Child Vaccination Histories File is provided with the public use data in order to make the calculation of exposure amounts transparent, and so that analysts have the potential to calculate alternative measures of exposure1.
    [Show full text]
  • Investigator's Brochure: Vaccinia Immune Globulin
    Use of Vaccinia Immune Globulin (VIG) For Treatment of vaccinia vaccine complications and for prophylaxis of unvaccinated individuals exposed to Orthopoxviruses responsive to VIG Investigational New Drug (IND) Proposal TABLE OF CONTENTS: 1. Introduction............................................................Page 2 2. Effects in Humans..................................................Pages 3 - 4 3. Nonclinical Studies.................................................Pages 5- 6 4. Rationale and Objectives.........................................Page 7 5. Study Design... .......................................................Page 8 6. Additional Information - Selected References..........Pages 9 - 15 Page -1- INVESTIGATOR’S BROCHURE INTRODUCTION This Investigational New Drug Application is being filed in order to make existing stocks of Vaccinia Immune Globulin available for treatment of complications of vaccinia vaccination or exposure to vaccinia or related pox viruses. Vaccinia Immune Globulin (VIG) (Human) is an isotonic sterile solution of the immunoglobulin fraction of plasma from persons vaccinated with vaccinia vaccine. The current lot, 0448A101A, was released as a licensed product by Baxter Healthcare Corporation in 1995. In 1998 a slight discoloration was noted in this product and the FDA placed a hold on its release. Consequently, VIG can no longer be entered into interstate commerce under terms of the approved license and must therefore revert to IND (investigational new drug) status. CDC follows the June 22, 2001 Recommendations of the Immunization Practices Advisory Committee (ACIP) for Vaccinia (Smallpox) Vaccine. Since 1983 CDC has provided vaccinia vaccine for laboratory workers directly involved with smallpox or closely related orthopox viruses (e.g., monkeypox and vaccinia). Due to clinical trials involving recombinant vaccinia virus vaccines, health-care workers (e.g., physicians and nurses) may now be exposed to vaccinia and recombinant vaccinia viruses and may be considered for vaccinia vaccination.
    [Show full text]
  • A Systematic Review of the Natural Virome of Anopheles Mosquitoes
    Review A Systematic Review of the Natural Virome of Anopheles Mosquitoes Ferdinand Nanfack Minkeu 1,2,3 and Kenneth D. Vernick 1,2,* 1 Institut Pasteur, Unit of Genetics and Genomics of Insect Vectors, Department of Parasites and Insect Vectors, 28 rue du Docteur Roux, 75015 Paris, France; [email protected] 2 CNRS, Unit of Evolutionary Genomics, Modeling and Health (UMR2000), 28 rue du Docteur Roux, 75015 Paris, France 3 Graduate School of Life Sciences ED515, Sorbonne Universities, UPMC Paris VI, 75252 Paris, France * Correspondence: [email protected]; Tel.: +33-1-4061-3642 Received: 7 April 2018; Accepted: 21 April 2018; Published: 25 April 2018 Abstract: Anopheles mosquitoes are vectors of human malaria, but they also harbor viruses, collectively termed the virome. The Anopheles virome is relatively poorly studied, and the number and function of viruses are unknown. Only the o’nyong-nyong arbovirus (ONNV) is known to be consistently transmitted to vertebrates by Anopheles mosquitoes. A systematic literature review searched four databases: PubMed, Web of Science, Scopus, and Lissa. In addition, online and print resources were searched manually. The searches yielded 259 records. After screening for eligibility criteria, we found at least 51 viruses reported in Anopheles, including viruses with potential to cause febrile disease if transmitted to humans or other vertebrates. Studies to date have not provided evidence that Anopheles consistently transmit and maintain arboviruses other than ONNV. However, anthropophilic Anopheles vectors of malaria are constantly exposed to arboviruses in human bloodmeals. It is possible that in malaria-endemic zones, febrile symptoms may be commonly misdiagnosed.
    [Show full text]
  • The Discovery, Distribution and Diversity of DNA Viruses
    bioRxiv preprint doi: https://doi.org/10.1101/2020.10.16.342956; this version posted March 17, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Title: The discovery, distribution and diversity of DNA viruses associated with Drosophila melanogaster in Europe Running title: DNA viruses of European Drosophila Key Words: DNA virus, Endogenous viral element, Drosophila, Nudivirus, Galbut virus, Filamentous virus, Adintovirus, Densovirus, Bidnavirus Authors: Megan A. Wallace 1,2 [email protected] 0000-0001-5367-420X Kelsey A. Coffman 3 [email protected] 0000-0002-7609-6286 Clément Gilbert 1,4 [email protected] 0000-0002-2131-7467 Sanjana Ravindran 2 [email protected] 0000-0003-0996-0262 Gregory F. Albery 5 [email protected] 0000-0001-6260-2662 Jessica Abbott 1,6 [email protected] 0000-0002-8743-2089 Eliza Argyridou 1,7 [email protected] 0000-0002-6890-4642 Paola Bellosta 1,8,9 [email protected] 0000-0003-1913-5661 Andrea J. Betancourt 1,10 [email protected] 0000-0001-9351-1413 Hervé Colinet 1,11 [email protected] 0000-0002-8806-3107 Katarina Eric 1,12 [email protected] 0000-0002-3456-2576 Amanda Glaser-Schmitt 1,7 [email protected] 0000-0002-1322-1000 Sonja Grath 1,7 [email protected] 0000-0003-3621-736X Mihailo Jelic 1,13 [email protected] 0000-0002-1637-0933 Maaria Kankare 1,14 [email protected] 0000-0003-1541-9050 Iryna Kozeretska 1,15 [email protected] 0000-0002-6485-1408 Volker Loeschcke 1,16 [email protected] 0000-0003-1450-0754 Catherine Montchamp-Moreau 1,4 [email protected] 0000-0002-5044-9709 Lino Ometto 1,17 [email protected] 0000-0002-2679-625X Banu Sebnem Onder 1,18 [email protected] 0000-0002-3003-248X Dorcas J.
    [Show full text]